3 results
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
To establish the MaximumTolerated Dose, Dose Limiting Toxicities, and the safety profile of BMS-833923 administered in combination with cisplatin and capecitabine as first-line therapy. To describe preliminary evidence of tumor response as measured…
The primary objective is to assess the neural short term changes, robotic gait therapy and tsDCS have on the corticospinal pathways. Thereby it has to be investigated in what kind of configuration and intensity tsDCS is most effective as well as…